» Articles » PMID: 25665066

The Multifaceted Role of Curcumin in Cancer Prevention and Treatment

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2015 Feb 10
PMID 25665066
Citations 150
Authors
Affiliations
Soon will be listed here.
Abstract

Despite significant advances in treatment modalities over the last decade, neither the incidence of the disease nor the mortality due to cancer has altered in the last thirty years. Available anti-cancer drugs exhibit limited efficacy, associated with severe side effects, and are also expensive. Thus identification of pharmacological agents that do not have these disadvantages is required. Curcumin, a polyphenolic compound derived from turmeric (Curcumin longa), is one such agent that has been extensively studied over the last three to four decades for its potential anti-inflammatory and/or anti-cancer effects. Curcumin has been found to suppress initiation, progression, and metastasis of a variety of tumors. These anti-cancer effects are predominantly mediated through its negative regulation of various transcription factors, growth factors, inflammatory cytokines, protein kinases, and other oncogenic molecules. It also abrogates proliferation of cancer cells by arresting them at different phases of the cell cycle and/or by inducing their apoptosis. The current review focuses on the diverse molecular targets modulated by curcumin that contribute to its efficacy against various human cancers.

Citing Articles

CUR-PDT induces ferroptosis of RA-FLS via the Nrf2/xCT/GPX4 pathway to inhibit proliferation in rheumatoid arthritis.

Sun L, Niu Y, Liao B, Liu L, Peng Y, Li K Inflamm Res. 2025; 74(1):53.

PMID: 40085199 DOI: 10.1007/s00011-025-02019-2.


Curcumin inhibits growth and triggers apoptosis in human castration-resistant prostate cancer cells via IGF-1/PI3K/Akt pathway.

Chen C, Wang Q, Liu J J Int Med Res. 2025; 53(2):3000605231220807.

PMID: 39921429 PMC: 11806470. DOI: 10.1177/03000605231220807.


The Dynamic Role of Curcumin in Mitigating Human Illnesses: Recent Advances in Therapeutic Applications.

Alam M, Jamir Anwar M, Maity M, Azam F, Jaremko M, Emwas A Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770516 PMC: 11679877. DOI: 10.3390/ph17121674.


Curcumin-mediated antimicrobial photodynamic therapy for inactivating Mycobacterium abscessus: a promising approach for non-tuberculous mycobacterial skin infections.

Dang Y, Yang R, Jia T, Liu C, Geng S Lasers Med Sci. 2025; 40(1):9.

PMID: 39762619 DOI: 10.1007/s10103-024-04263-0.


Nanocodelivery of 5-Fluorouracil and Curcumin by RGD-Decorated Nanoliposomes Achieves Synergistic Chemotherapy for Breast Cancer.

Mahmoudi R, Mohammadi S, Mahmoudi R, Fouani M, Ardakani M, Hadi A IET Nanobiotechnol. 2024; 2024:4959295.

PMID: 39629226 PMC: 11614510. DOI: 10.1049/nbt2/4959295.


References
1.
Egen C, Wehinger J, Ludwig W, Gouilleux-Gruart V, Mertelsmann R, Finke J . Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood. 1996; 88(3):809-16. View

2.
Naksuriya O, Okonogi S, Schiffelers R, Hennink W . Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014; 35(10):3365-83. DOI: 10.1016/j.biomaterials.2013.12.090. View

3.
Sundram V, Chauhan S, Ebeling M, Jaggi M . Curcumin attenuates β-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS One. 2012; 7(4):e35368. PMC: 3327669. DOI: 10.1371/journal.pone.0035368. View

4.
Sun Z, Chen G, Zhang W, Hu X, Liu Y, Zhou Q . Curcumin dually inhibits both mammalian target of rapamycin and nuclear factor-κB pathways through a crossed phosphatidylinositol 3-kinase/Akt/IκB kinase complex signaling axis in adenoid cystic carcinoma. Mol Pharmacol. 2010; 79(1):106-18. DOI: 10.1124/mol.110.066910. View

5.
Schaaf C, Shan B, Buchfelder M, Losa M, Kreutzer J, Rachinger W . Curcumin acts as anti-tumorigenic and hormone-suppressive agent in murine and human pituitary tumour cells in vitro and in vivo. Endocr Relat Cancer. 2009; 16(4):1339-50. DOI: 10.1677/ERC-09-0129. View